

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to Fabian Schmidt, Frauke Muecksch, Yiska Weisblum, Justin Da Silva, Eva Bednarski, Alice Cho, Zijun Zhang, Christian Gaebler, Marina Caskey, Michel C. Nussenzweig, Theodora Hatzioannou, and Paul D. Bieniasz Plasma neutralization properties of the SARS-CoV-2 Omicron variant

Table S1. Individual convalescent participant characteristics

ID	Age (years)	Sex	Temporal dynamics (days)		Vaccination status		
			Sx onset to initial visit (1.3m)	Sx onset to follow-up visit (1y)	Vaccine received	# of doses received prior to 1y	Days between first dose
8	36-40	M	57	370	N	N/A	N/A
9	31-35	F	53	366	N	N/A	N/A
21	51-55	M	27	340	N	N/A	N/A
38	56-60	F	38	337	N	N/A	N/A
40	41-45	M	23	345	N	N/A	N/A
46	36-40	M	30	337	N	N/A	N/A
47	41-45	F	33	340	N	N/A	N/A
72	41-45	M	35	352	N	N/A	N/A
75	46-50	F	36	340	N	N/A	N/A
76	46-50	F	34	379	N	N/A	N/A
328	51-55	F	62	365	N	N/A	N/A
353	56-60	M	49	366	N	N/A	N/A
403	51-55	M	39	356	N	N/A	N/A
410	31-35	M	46	349	N	N/A	N/A
437	41-45	F	34	353	N	N/A	N/A
461	46-50	M	39	350	N	N/A	N/A
501	31-35	M	53	367	N	N/A	N/A
507	36-40	M	60	361	N	N/A	N/A
547	56-60	M	36	359	N	N/A	N/A
633	36-40	M	57	358	N	N/A	N/A
7	36-40	M	30	376	Pfizer-BNT	2	65
20	26-30	F	17	345	Moderna	2	35
24	31-35	M	30	336	Pfizer-BNT	N/A	N/A
55	36-40	M	49	349	Moderna	2	41
71	41-45	F	48	386	Pfizer-BNT	2	62
96	46-50	F	30	359	Pfizer-BNT	2	54
115	61-65	F	41	335	Moderna	1	12
120	56-60	F	48	375	Moderna	2	67
135	61-65	F	31	341	Moderna	1	27
186	36-40	F	33	356	Pfizer-BNT	2	73
222	26-30	M	37	347	Pfizer-BNT	2	41
230	46-50	M	33	372	Pfizer-BNT	N/A	N/A
233	51-55	M	41	377	Moderna	1	8
325	51-55	M	38	353	Moderna	2	49
393	66-70	M	54	362	Moderna	2	57
394	46-50	F	67	375	Moderna	N/A	N/A
401	61-65	M	53	371	Pfizer-BNT	1	18
500	46-50	M	53	375	Pfizer-BNT	1	20
537	51-55	M	45	357	Pfizer-BNT	1	14
539	71-75	F	55	362	Pfizer-BNT	2	50

Table S2. Individual vaccinated participant characteristics

ID	Age (years)	Sex	Vaccine platform			Vaccination time line (days)				
			1st dose	2nd dose	3rd dose	1st to 2nd dose	2nd to 3rd dose	2nd (mRNA)/ 1st (J&J) dose to 1st visit	2nd (mRNA)/ 1st (J&J) dose to 2nd visit	3rd (mRNA) dose to Follow-up
C001	36-40	F	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	22	251	35	133	56
C002	41-45	M	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	373	79	177	27
C004	36-40	M	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	389	70	170	27
C005	46-50	M	Moderna	Moderna	Pfizer-BNT	28	326	91	175	94
C006	61-65	M	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	246	22	146	22
C007	26-30	M	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	252	37	141	21
C008	51-55	F	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	244	35	141	28
C009	31-35	F	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	244	36	141	22
C010	66-70	F	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	245	34	146	21
C011	71-75	F	Moderna	Moderna	Pfizer-BNT	28	274	28	131	21
C017	21-25	M	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	252	21	244	21
C018	21-25	F	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	242	48	172	23
C019	31-35	M	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	245	34	146	21
C021	36-40	F	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	212	28	168	47
C028	21-25	M	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	252	41	168	28
C029	56-60	F	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	244	49	166	22
C031	26-30	M	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	21	242	37	165	28
C034	36-40	F	Pfizer-BNT	Pfizer-BNT	Pfizer-BNT	24	273	31	245	19
C055	36-40	F	J&J	-	-	-	-	34	175	-
C056	56-60	F	J&J	-	-	-	-	52	187	-
C057	26-30	M	J&J	-	-	-	-	44	178	-
C059	21-25	F	J&J	-	-	-	-	44	181	-
C060	51-55	M	J&J	-	-	-	-	35	191	-
C061	46-50	F	J&J	-	-	-	-	27	177	-
C062	31-35	F	J&J	-	-	-	-	53	200	-
C064	36-40	F	J&J	-	-	-	-	46	178	-
C066	46-50	F	J&J	-	-	-	-	50	183	-
C067	46-50	F	J&J	-	-	-	-	52	193	-
C069	51-55	F	J&J	-	-	-	-	37	172	-
C070	41-45	M	J&J	-	-	-	-	67	187	-
C072	41-45	F	J&J	-	-	-	-	63	150	-
C073	41-45	F	J&J	-	-	-	-	56	197	-
C075	31-35	M	J&J	-	-	-	-	72	180	-
C076	31-35	M	J&J	-	-	-	-	72	179	-
C079	51-55	M	J&J	-	-	-	-	46	152	-
C080	31-35	M	J&J	-	-	-	-	34	140	-
C081	41-45	M	J&J	-	-	-	-	31	136	-